Researchers tracked patients for five years. An outside expert says the 44% relative drop works out to roughly 3 to 5 percentage points.
Recap by typeshit. Full story at Yahoo Health.
6:25
Dr Almerie compares Lilly's experimental retatrutide with Mounjaro and talks through the case for switching versus holding off until it's approved.
He points to GLP-1 receptors in the hypothalamus, saying the medication boosts fullness signals and slows the stomach, which changes how hunger feels.
10:08
Weight loss doctor Bazgha Khalid goes through what the published trials actually show for Zepbound against Lilly's newer retatrutide.
Patients who took a GLP-1 receptor agonist before surgery did not lose more weight at one year, JAMA Surgery reports. The full study has the details.
A group of MPs is pressing for faster access to Mounjaro through the NHS, Sky News reports.
AG Information Network of the West looks at GLP-1 users' effect on protein demand, alongside news on a US trade deal with Mexico.
Loading…